X4 Pharma Q1 net loss $24.0M; cash $94.4M into Q2 2024; mavorixafor NDA on track

X4 Pharmaceuticals, Inc

2022-Q3 EPS reported -$0.16

Net loss of $24.0M in Q1 2023 vs $22.0M in Q1 2022; R&D expenses $22.1M including $5.0M milestone accrual.
Cash, equivalents & restricted cash $94.4M as of March 31, 2023; sufficient to fund operations into Q2 2024.
U.S. NDA submission for mavorixafor in WHIM syndrome on track for early second half of 2023.
Phase 3 WHIM trial infection data to be presented at May 16 webinar and May 21 CIS oral presentation.
Phase 2 chronic neutropenia trial data and regulatory path clarity expected in Q2/Q3 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

X4 Pharmaceuticals, Inc reported financial results for first quarter ended March 31, 2023.

Period: first quarter ended March 31, 2023
Result: reported results

Exact text from the filing

On May 4, 2023, X4 Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results and other business highlights for the first quarter ended March 31, 2023.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

X4 Pharmaceuticals, Inc filing history →

Source: SEC EDGAR

accession 0001628280-23-015415

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.